Anti CX3CR1

Figure 1 Western Blot Validation in Human Cells
Loading: 15 μg of lysates per lane.Antibodies: CX3CR1 2093 (0.5 μg/mL), 1h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.

Figure 2 KD Validation in 293 Cells
Loading: 15 μg of lysates per lane.Antibodies: CX3CR1 2093 (0.5 μg/mL), 1h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.Lane 1: 293 cells transfected with control siRNAs.Lane 2: 293 cells transfected with CX3CR1 siRNAs.

Figure 3 Western Blot Validation in THP1 Cells
Loading: 15 μg of lysates per lane.Antibodies: CX3CR1 2093 (1 μg/mL), 1h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.Lane 1: 0.2 μg/mLLane 1: 0.5 μg/mLLane 1: 1 μg/mL

Figure 4 Western Blot Validation in Human Spleen Lysates
Loading: 15 μg of lysates per lane.Antibodies: CX3CR1 2093 (1 μg/mL) in the absence (lane 1) or presence of blocking peptide (lane 2), 1h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.

Figure 5 Western Blot Validation in Rat Spleen Tissue
Loading: 15 μg of lysates per lane.Antibodies: CX3CR1 2093, (A; 1 μg/mL, B; 2 μg/mL), 1h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.

Figure 6 Flow Cytometry Validation of CX3CR1 in THP-1 Cells
Overlay histogram showing THP-1 cells stained with 2093 (red line, 1μg/1x10⁶ cells). 1 h incubation at 4℃ in 2% FBS/PBS. Followed by secondary antibody 488 goat anti-rabbit IgG (H+L) at 1/500 dilution for 1 h 4℃.

Isotype control antibody (Green line) was rabbit IgG1 (1μg/1x10⁶ cells) used under the same conditions. Acquisition of >10,000 events was performed.

Figure 7 Immunofluorescence Validation of CX3CR1 In K562 Cells
Immunofluorescent analysis of 4% paraformaldehyde-fixed K562 cells labeling CX3CR1 with 2093 at 10 μg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (red) and DAPI staining (blue). Image showing membrane staining on K562 cells.

Figure 8 Immunofluorescence Validation of CX3CR1 in Human Heart
Immunofluorescent analysis of 4% paraformaldehyde-fixed human heart tissue labeling CX3CR1 with 2093 at 10 μg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (red).

Figure 9 Immunofluorescence Validation of CX3CR1 in Mouse Heart Tissue
Immunofluorescent analysis of 4% paraformaldehyde-fixed mouse heart tissue labeling CX3CR1 with 2093 at 20 μg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (green) and DAPI staining (blue).

Figure 10 Immunohistochemistry Validation of CX3CR1 in Rat Heart Tissue
Immunohistochemical analysis of paraffin-embedded rat heart tissue using anti-CX3CR1 antibody (2093) at 2 μg/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4℃. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.